Recent developments in donepezil-based hybrid molecules as multi-target therapeutics for Alzheimer's disease: A paradigm shift beyond symptomatic treatment.

Nitin Kumar; Izhar Khan; Jyoti Singh; Krishan Kumar; Virendra Kumar Kushwaha; Smriti Ojha; Sunil Kumar Raman; Gauri Shankar

doi:10.1016/j.bioorg.2026.110361

SCHEDA SCIENTIFICA2026Altra ricerca

Recent developments in donepezil-based hybrid molecules as multi-target therapeutics for Alzheimer's disease: A paradigm shift beyond symptomatic treatment.

Nitin Kumar, Izhar Khan, Jyoti Singh, Krishan Kumar, Virendra Kumar Kushwaha, Smriti Ojha, Sunil Kumar Raman, Gauri Shankar

Bioorganic chemistry · 2026

Psicologia clinica Psicoterapia Neuroscienze Psicologia cognitiva

Abstract e pubblicazione originale

L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.

Leggi nella fonte originale ↗

Parole chiave

HumansAlzheimer DiseaseDonepezilCholinesterase InhibitorsStructure-Activity RelationshipAnimalsMolecular StructureNeuroprotective AgentsAcetylcholinesteraseAlzheimer's diseaseButyrylcholinesteraseDPZMDTLs

Come citare questo studio

Nitin Kumar, Izhar Khan, Jyoti Singh, Krishan Kumar, Virendra Kumar Kushwaha, Smriti Ojha, Sunil Kumar Raman, Gauri Shankar. (2026). Recent developments in donepezil-based hybrid molecules as multi-target therapeutics for Alzheimer's disease: A paradigm shift beyond symptomatic treatment.. Bioorganic chemistry. DOI: 10.1016/j.bioorg.2026.110361

Consulta la pubblicazione originale ↗